🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

APPLAUSE, APPLAUSE Vlado Perkovic Jonathan Barratt Brad H Rovin et al Iptacopan reduces proteinurie (PU) in IgA NP 🐘1: Is the effect additive to SGLT2I (low use in APPLAUSE) 🐘2: How long to treat with iptacopan? 🐘3: Will low PU be longterm renoprotective? nejm.org/doi/full/10.10…

Nice summary from the Oxford Population Health (OxPop) team: “ …while empagliflozin continues to have some benefit after stopping treatment, the effects are smaller than when taking empagliflozin and short lived. Maximising the benefits of such medicines in #CKD requires long-term treatment.’

It was 50% not on KRT by end of 2y post-EMPA-K not treated with #SGLT2i. Regulators globally have been so supportive with accelerated review. We clinicians need 2 b as fast with implementation. Open-label extension studies ought 2 b the norm (thx for flozinator badge Swapnil Hiremath @hswapnil.medsky.social)

Pretty chuffed with 2024 #KidneyWk fridge decoration haul! Swapnil Hiremath @hswapnil.medsky.social KDIGO ERA - European Renal Association Int Society of Nephrology American Society of Nephrology Looking forward to some big trial results in Houston 2025 @lastwalsh ?

Want to know more about #clinicaltrials? Apply for our part-time #MSc in Clinical Trials to receive in-depth training in conducting large-scale, randomised clinical trials from world leading experts. 🎓 Apply now 👉 buff.ly/3UviNW8

We're going back...to the future of #FLOZINATION!! This #NephJC we'll discuss long-term effects of empagliflozin on CKD & revisit the EMPA-KIDNEY study participants. Join us 11/5/24 at 9pm EST or 11/6/24 at 9pm IST. nephjc.com/news/empa-long…

Nephrology Journal Club #NephJC

#NephJC

8/10 #NephJC Quote of the fortnight from Will Herrington 👇

🎥Watch Dr Kaitlin Mayne present the NDT publication: Empagliflozin lowers serum uric acid in CKD: exploratory analyses from the EMPA-KIDNEY trial In only 3 minutes, Kaitlin Mayne gives the main results of this study: oup.cloud.panopto.eu/Panopto/Pages/…

Important care gap highlighted by the EMPA KIDNEY post-trial follow up: 1 in 4 people with diabetes on SGLT2i who were hospitalised for #heartfailure didnt restart SGLT2i within 12 months of discharge SGLT2i discontinuation analysis led by Tamie Milder: dom-pubs.onlinelibrary.wiley.com/doi/10.1111/do…

Joel M. Topf, MD FACP & Roger Rodby killing it on stage as 'Sherlock Holmes' & 'John Watson' (by turn) at the ApEx Pathsala, Mumbai, teaching how to solve Fluid & Electrolyte mysteries!! Exceptionally Enlightening & Entertaining!!

Prof Will Herrington discusses the EMPA-KIDNEY trial on long-term effects of #empagliflozin in patients with #CKD. 📽️Watch here👉 ow.ly/f15x50UomXA #SGLT2 #CardioRenal #CVRM #CardioTwitter

Our latest video in our partnership with Dr. Glaucomflecken explains the results of the RESHAPE-HF2 trial investigating whether transcatheter mitral-valve repair improves outcomes in patients with heart failure and functional mitral regurgitation. nej.md/40sCr7s

Editors’ Choice 2024: Frailty, Multimorbidity, and Polypharmacy: Exploratory Analyses of the Effects of Empagliflozin from the EMPA-KIDNEY Trial This study's findings support the use of sodium-glucose cotransporter-2 inhibitors in CKD, irrespective of frailty, multimorbidity, or

If you haven’t heard why Oxford Renal Studies Grp believe innovations in conduct of trials r more important than developing surrogates & new analytic methods then this is your bedtime read 4 tonight!!! Not exhilarating, until you see the magic of examples. academic.oup.com/ndt/article/40…

Great to see post trial follow-up of a CVOT! EMPAKIDNEY Empagliflozin continued to have additional cardiorenal benefits for up to 12 months after it was discontinued. NEJM

Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease | ⁦NEJM⁩ nejm.org/doi/full/10.10…

In case you missed our Journal Club (ERA - European Renal Association) yesterday. The proposal of DMAND definition was presented by LuVaCs Leiden yesterday!